Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408927 | 0.86 | MAOB (0.56) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL28125444 | 0.85 | S1PR1 (0.51) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL13596044 | 0.84 | MAPT (0.65) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3844659 | 0.80 | MAOB (0.52) | RAB9ASMN1; SMN2S1PR1MAPTNR4A2 | |
| SCHEMBL3825466 | 0.79 | DHODH (0.47) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6031320 | 0.77 | KDM4E (0.57) | S1PR1ALDH1A1SMPD1NR4A2MAOB | |
| SCHEMBL6031317 | 0.77 | KDM4E (0.57) | S1PR1ALDH1A1SMPD1NR4A2MAOB | |
| SCHEMBL3085911 | 0.77 | MAOB (0.52) | NPC1RAB9AS1PR1ALDH1A1NR4A2 | |
| SCHEMBL14295927 | 0.77 | S1PR1 (0.48) | SMN1; SMN2MEN1KMT2AS1PR1SMPD1 | |
| SCHEMBL3832329 | 0.76 | ALDH1A1 (0.43) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318389-A1 | AGONISTS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318389-A1 | AGONISTS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318389-A1 | AGONISTS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2099768-A2 | AGONISTS OF THE SPHINGOSINE-1-PHOSPHATE RECEPTOR | Praecis Pharmaceuticals Incorporated (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008019090-A2 | AGONISTS OF THE SPHINGOSINE-1-PHOSPHATE RECEPTOR | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008019090-A2 | AGONISTS OF THE SPHINGOSINE-1-PHOSPHATE RECEPTOR | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318389-A1 | AGONISTS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR | S1PR1, S1PR3, S1PR5 | NPC1 1484/4885RAB9A 1514/4885SMN1; SMN2 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.